Contact Us
Production Schedule
SCIENCE
Why InSphero?
Enabling Technology
3D Select™ Process
Microtissue Formats
Organ-on-a-chip Systems
Live Microtissue Shipping
Publications
Peer-reviewed Papers
White Papers
Posters
Blog
Webinars
APPLICATIONS
Application Overview
Liver Toxicology
DILI Prediction
Mechanistic Assays
Diabetes and NASH Discovery
Islet
Liver
Oncology
Efficacy Testing
Immuno-oncology
Other
PRODUCTS
3D InSight™ Platforms
Liver
Liver Disease
NASH
Fibrosis
Platform Add-Ons
Liver Toxicology
Human
Animal
Islet
Human
Rat
Platform Add-Ons
Tumor
Assay-ready Models
Custom Model Development
How to Order
SERVICES
Services Overview
In Vitro
Toxicology
14 Day Hepatotoxicity
Custom Mechanistic and Investigative Studies
Mitochondrial Toxicity
Pancreatic Endocrine Toxicity
Embryotoxicity (DART)
Diabetes and NASH Drug Discovery
Diabetes Drug Testing
Oncology Drug Discovery
Custom Tumor Model Development
Efficacy Testing
Combinatorial Drug Testing
Tumor Relapse Assay
Antibody Penetration
How to Get Started
ABOUT
About InSphero
Leadership
Careers
Contact Us
Our Partners
News & Events
Newsletter
Media Releases
Fairs, Conferences & Events
SUPPORT
Help Center
Production Schedule
Protocols and Manuals
Customer Portal
BLOG
InSphero_difference_icon2
Contact Us
Production Schedule
News
Check out our new blog page where our scientists discuss InSphero 3D Platforms for Drug Discovery and Efficacy Testing. Read our blogs >>
InSphero launches powerful new human liver disease model for anti-fibrotic drug discovery. Read More >>
AstraZeneca & Genentech publish comprehensive evaluation of 3D InSight™ Microtissues for DILI prediction. Read More >>
InSphero achieves new milestone with Akura™ Flow organ-on-a-chip technology. Read the policy >>
InSphero partners with ALPCO to advance diabetes research. Read more >>
